Lumosa Therapeutics Co (ROCO:6535) Short Interest


ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$97.00
GF Value NT$130.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ROCO:6535 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Lumosa Therapeutics Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumosa Therapeutics Co Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Short Interest distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's Short Interest falls into.


ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$97.00 is trading 25.8% below its estimated GF Value™ of NT$130.67. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Short Interest:
  • GF Value™: NT$130.67 vs. price of NT$97.00 (25.8% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$97.00
Price
NT$130.67
GF Value